대한뉴팜

The company announced on the 11th that it achieved an accumulated operating profit of 22.1 billion won in the third quarter of 2021, marking a 12% increase year-on-year. Revenue grew 10% to 125.6 billion won, while net profit surged 123% to 14 billion won. All financial indicators showed improvement, with the current ratio—a measure of financial stability—rising by 42.8 percentage points to 179%, and the debt ratio decreasing by 36 percentage points to 96%.

The pharmaceutical division contributed to sales growth through the launch of the new dyslipidemia combination drug “Newtozet” and the domestically exclusive carbohydrate absorption inhibitor “Migbos Film-Coated Tablet.” The company is also preparing to expand its diabetes medication portfolio next year by launching a generic version of a DPP-4 inhibitor, aiming to further boost revenue with new product introductions.

In the health supplement division, the company is expanding its “DiNU (Define Nutrition)” brand, launched in the second half of this year. Starting with a dual-functional propolis combining Brazilian green propolis and vitamin C, it has released 3g of ascorbic acid from DSM (UK) and OptiMSM from the U.S. On the 11th, it will introduce “Pharaotics,” a probiotic product utilizing Korea’s first “cap-in-cap” technology.

In the animal health division, the company plans to obtain product approval for “Trax Injection,” an antibacterial treatment for livestock respiratory diseases, with a commercial launch scheduled for this year. Since the patent expiration in the second half of 2019, domestic manufacturers have been able to produce and sell tulathromycin-based products. The tulathromycin market has grown from around 3 billion won before the patent expiry to approximately 9 billion won, and this product is expected to contribute to sales growth.

The company continues to invest steadily in research and development across human pharmaceuticals, veterinary medicines, biopharmaceuticals, and health supplements, with new product launches progressing as planned. By achieving its fourth-quarter goals, the company aims to successfully close 2021 and move forward toward meeting its three-year targets through active recruitment in management, sales, R&D, and manufacturing.